The concept of vascular “normalization” by anti-VEGF agents for improved drug delivery and efficacy is the basis of anti-angiogenic treatments (e.g., bevacizumab) which has been approved for treatment of metastatic colorectal cancer. Here, VEGFA is linked to metastatic colorectal cancer.